Suzanne L Epstein

List of Publications by Year
in descending order

58 papers	3,526 citations	236925 25 h-index	168389 53 g-index
58 all docs	58 docs citations	58 times ranked	3482 citing authors

#	Article	IF	Citations
1	Mice Deficient in Nuclear Factor (NF)-Î°B/p52 Present with Defects in Humoral Responses, Germinal Center Reactions, and Splenic Microarchitecture. Journal of Experimental Medicine, 1998, 187, 147-159.	8.5	412
2	Protection against lethal influenza virus challenge by RNA interferencein vivo. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8682-8686.	7.1	366
3	Prior H1N1 Influenza Infection and Susceptibility of Cleveland Family Study Participants during the H2N2 Pandemic of 1957: An Experiment of Nature. Journal of Infectious Diseases, 2006, 193, 49-53.	4.0	288
4	Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1. Emerging Infectious Diseases, 2007, 13, 426-435.	4.3	256
5	Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine, 2005, 23, 5404-5410.	3.8	254
6	Critical Roles for the Bcl-3 Oncoprotein in T Cellâ€“Mediated Immunity, Splenic Microarchitecture, and Germinal Center Reactions. Immunity, 1997, 6, 479-490.	14.3	177
7	TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection. Journal of Immunology, 2011, 186, 2422-2429.	0.8	167
8	Interferon (IFN) Consensus Sequence-binding Protein, a Transcription Factor of the IFN Regulatory Factor Family, Regulates Immune Responses In Vivo through Control of Interleukin 12 Expression. Journal of Experimental Medicine, 1997, 186, 1535-1546.	8.5	153
9	DNA Vaccine Expressing Conserved Influenza Virus Proteins Protective Against H5N1 Challenge Infection in Mice. Emerging Infectious Diseases, 2002, 8, 796-801.	4.3	153
10	Heterosubtypic Immunity to Influenza A Virus in Mice Lacking IgA, All Ig, NKT Cells, or Î³Î´ T Cells. Journal of Immunology, 2001, 166, 7437-7445.	0.8	127
11	Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine, 2009, 27, 6512-6521.	3.8	114
12	Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses. PLoS ONE, 2010, 5, e13162.	2.5	110
13	Cross-protective immunity to influenza A viruses. Expert Review of Vaccines, 2010, 9, 1325-1341.	4.4	105
14	Induction of anti-Hâ€“2 antibodies without alloantigen exposure by in vivo administration of anti-idiotype. Nature, 1981, 291, 233-235.	27.8	71
15	Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: Cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine, 2008, 26, 2062-2072.	3.8	70
16	Vaccination with DNA encoding internal proteins of influenza virus does not require CD8+ cytotoxic T lymphocytes: either CD4+ or CD8+ T cells can promote survival and recovery after challenge. International Immunology, 2000, 12, 91-101.	4.0	67
17	Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3173-3177.	7.1	60
18	A cell surface ELISA in the mouse using only poly-l-lysine as cell fixative. Journal of Immunological Methods, 1985, 76, 63-72.	1.4	50

#	Article	IF	Citations
19	Mucosal Immunization with a Candidate Universal Influenza Vaccine Reduces Virus Transmission in a Mouse Model. Journal of Virology, 2014, 88, 6019-6030.	3.4	49
20	Control of influenza virus infection by immunity to conserved viral features. Expert Review of Anti-Infective Therapy, 2003, 1, 627-638.	4.4	46
21	Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus. PLoS ONE, 2013, 8, e55435.	2.5	43
22	Cold-Adapted Influenza and Recombinant Adenovirus Vaccines Induce Cross-Protective Immunity against pH1N1 Challenge in Mice. PLoS ONE, 2011, 6, e21937.	2.5	42
23	First flu is forever. Science, 2016, 354, 706-707.	12.6	33
24	Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine, 2010, 28, 5817-5827.	3.8	30
25	Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo. American Journal of Epidemiology, 2018, 187, 2603-2614.	3.4	27
26	Regulatory Concerns in Human Gene Therapy. Human Gene Therapy, 1991, 2, 243-249.	2.7	23
27	Idiotypic Manipulation of the Immune Response to Transplantation Antigens. Immunological Reviews, 1986, 90, 5-28.	6.0	22
28	Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine. PLoS Pathogens, 2020, 16, e1008583.	4.7	22
29	Mouse Monoclonal Antibodies to Human Immunodeficiency Virus Glycoprotein 120 Generated by Repeated Immunization with Glycoprotein 120 from a Single Isolate, or by Sequential Immunization with Glycoprotein 120 from Three Isolates. Hybridoma, 1995, 14, 235-242.	0.6	19
30	Intranasal Administration of Adeno-associated Virus Type 12 (AAV12) Leads to Transduction of the Nasal Epithelia and Can Initiate Transgene-specific Immune Response. Molecular Therapy, 2011, 19, 1990-1998.	8.2	18
31	Continuing to strengthen FDA's science approach to emerging technologies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 594-599.	3.3	14
32	Age Dependence of Immunity Induced by a Candidate Universal Influenza Vaccine in Mice. PLoS ONE, 2016, 11, e0153195.	2.5	14
33	Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice. Vaccine, 2021, 39, 4628-4640.	3.8	13
34	Reduction of influenza virus transmission from mice immunized against conserved viral antigens is influenced by route of immunization and choice of vaccine antigen. Vaccine, 2018, 36, 4910-4918.	3.8	11
35	The presence of a common idiotype in anti-H-2 immune sera as detected by anti-idiotype to a monoclonal anti-H-2 antibody. European Journal of Immunology, 1983, 13, 13-18.	2.9	10
36	Eight new MHC recombinant strains defining at least six H-2 haplotypes. Immunogenetics, 1986, 24, 135-138.	2.4	8

#	Article	IF	Citations
37	Anti-Leu3a Induces Combining Site-Related Anti-idiotypic Antibody Without Inducing Anti-HTV Activity. AIDS Research and Human Retroviruses, 1991, 7, 55-63.	1.1	7
38	Conventional influenza vaccines influence the performance of a universal influenza vaccine in mice. Vaccine, 2018, 36, 1008-1015.	3.8	7
39	Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model. Journal of Virology, 2021, 95, .	3.4	7
40	Induction of antigen-specific immunity with monoclonal anti-idiotypic antibodiesin vivo: differences in potency and comparison of immunochemical. European Journal of Immunology, 1989, 19, 2361-2365.	2.9	6
41	FDA comments on phase I clinical trials without vector biodistribution data. Nature Genetics, 1999, 22, 326-326.	21.4	6
42	Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic. Open Forum Infectious Diseases, 2017, 4, ofx023.	0.9	6
43	The I-J dilemma: new developments. Trends in Immunology, 1984, 5, 94-95.	7.5	5
44	Recombinant human CD4 elicits antibody responses different in epitope specificity from those that cellular CD4 elicits. Molecular Immunology, 1993, 30, 765-773.	2.2	5
45	T-Cell Immune Responses and Asymptomatic H5N1 Influenza Infection. Journal of Infectious Diseases, 2012, 205, 4-6.	4.0	5
46	The effect of respiratory viruses on immunogenicity and protection induced by a candidate universal influenza vaccine in mice. PLoS ONE, 2019, 14, e0215321.	2.5	5
47	Idiotypes of Anti-MHC Monoclonal Antibodies. , 1984, , 243-269.		5
48	Survey of Human Antibody Responses to Influenza Virus Matrix Protein 2 by Use of a Sensitive Flow Cytometric Method. Journal of Infectious Diseases, 2014, 209, 975-977.	4.0	4
49	Immunoglobulin classes and subclasses in alloantisera to mouse thymocyte surface antigens. Immunogenetics, 1979, 8, 517-528.	2.4	3
50	Idiotypes of Anti-Major Histocompatibility Complex Antibodies. Annals of the New York Academy of Sciences, 1983, 418, 265-271.	3.8	3
51	Critical Path Workshop on the Development of Cellular and Gene Therapy Products. Molecular Therapy, 2005, 12, 5-8.	8.2	2
52	Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal Vaccine Candidate is Long-Lasting and Does Not Require Antibodies. Journal of Virology, 2022, 96, .	3.4	2
53	Characterization of a dominant anti-Ia idiotype using the Ia mutant mouse strain B6.C-H-2bm12. Molecular Immunology, 1985, 22, 417-426.	2.2	1
54	Letter to the editor. Molecular Immunology, 1991, 28, 193.	2.2	1

#	Article	IF	Citations
55	Vaccination with DNA encoding conserved influenza viral proteins. International Congress Series, 2001, 1219, 905-910.	0.2	1
56	Expression of Anti-MHC Idiotypes in Immune Responses. , 1984, , 279-297.		1
57	FDA research. Nature Medicine, 1997, 3, 816-816.	30.7	0
58	Susceptibility and immunity to influenza A strains in Igâˆ’/âˆ’mice. International Congress Series, 2001, 1219, 327-332.	0.2	0